AI Article Synopsis
- Scientists tested two drugs, binimetinib and ribociclib, on patients with a type of skin cancer called melanoma that has a specific mutation.
- In a study, they found that about 19.5% of the patients responded well to the treatment.
- Additionally, on average, patients went 3.7 months without their cancer getting worse after starting the drugs.
Article Abstract
In the search for targeting MAPK plus other pathways in NRAS-mutant melanoma, a phase Ib/II trial tested binimetinib plus ribociclib in metastatic melanoma. The response rate in the phase II trial was 19.5%, and the median progression-free survival was 3.7 months. See related article by Schuler et al., p. 3002.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1158/1078-0432.CCR-22-1256 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Atomic-level mechanisms of abnormal activation in NRAS oncogenes from two-dimensional free energy landscapes.
Nanoscale
January 2025
Department of Physics, Polytechnic University of Catalonia-Barcelona Tech, B5-209 Northern Campus, Jordi Girona 1-3, 08034 Barcelona, Catalonia, Spain.
The NRAS-mutant subset of melanoma is one of the most aggressive and lethal types associated with poor overall survival. Unfortunately, a low understanding of the NRAS-mutant dynamic behavior has led to the lack of clinically approved therapeutic agents able to directly target NRAS oncogenes. In this work, accurate local structures of NRAS and its mutants have been fully explored through the corresponding free energy surfaces obtained by microsecond scale well-tempered metadynamics simulations.
View Article and Find Full Text PDFRegorafenib Combined with BRAF/MEK Inhibitors for the Treatment of Refractory Melanoma Brain Metastases.
Cancers (Basel)
December 2024
Team Laboratory for Medical and Molecular Oncology (LMMO), Translational Oncology Research Center (TORC), Vrije Universiteit Brussel (VUB), Universitair Ziekenhuis Brussel (UZ Brussel), Laarbeeklaan 101, 1090 Brussels, Belgium.
Background: There are no active treatment options for patients with progressive melanoma brain metastases (MBM) failing immune checkpoint blockade (ICB) and BRAF/MEK inhibitors (BRAF/MEKi). Regorafenib (REGO), an oral multi-kinase inhibitor (incl. RAF-dimer inhibition), can overcome adaptive resistance to BRAF/MEKi in preclinical models.
View Article and Find Full Text PDFA phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer.
Lung Cancer
November 2024
Department of Respiratory Diseases, University Hospitals KU Leuven, Leuven, Belgium; Department of Chronic Diseases and Metabolism, Respiratory Oncology Unit, Laboratory of Respiratory Diseases and Thoracic Surgery, KU Leuven, Leuven, Belgium.
Article Synopsis
- The study focused on pairing naporafenib, a pan-RAF inhibitor, with either rineterkib or trametinib to treat patients with non-small cell lung cancer (NSCLC) and certain genetic mutations.
- Conducted on 216 patients, the research aimed to find safe and effective dosage levels, identifying recommended doses while monitoring for side effects and antitumor activity.
- Results showed dose-limiting toxicities in 16% of patients, with some achieving partial responses; the study established specific dosages that were well-tolerated along with noticeable reductions in certain mRNA levels.
Computational Modeling of Drug Response Identifies Mutant-Specific Constraints for Dosing panRAF and MEK Inhibitors in Melanoma.
Cancers (Basel)
August 2024
gRED Computational Sciences, Genentech, South San Francisco, CA 94080, USA.
Purpose: This study explores the potential of pre-clinical in vitro cell line response data and computational modeling in identifying the optimal dosage requirements of pan-RAF (Belvarafenib) and MEK (Cobimetinib) inhibitors in melanoma treatment. Our research is motivated by the critical role of drug combinations in enhancing anti-cancer responses and the need to close the knowledge gap around selecting effective dosing strategies to maximize their potential.
Results: In a drug combination screen of 43 melanoma cell lines, we identified specific dosage landscapes of panRAF and MEK inhibitors for NRAS vs.
Computational modeling of drug response identifies mutant-specific constraints for dosing panRAF and MEK inhibitors in melanoma.
bioRxiv
August 2024
gRED Computational Sciences, Genentech, South San Francisco, CA, US.
Purpose: This study explores the potential of preclinical cell line response data and computational modeling in identifying optimal dosage requirements of pan-RAF (Belvarafenib) and MEK (Cobimetinib) inhibitors in melanoma treatment. Our research is motivated by the critical role of drug combinations in enhancing anti-cancer responses and the need to close the knowledge gap around selecting effective dosing strategies to maximize their potential.
Results: In a drug combination screen of 43 melanoma cell lines, we identified unique dosage landscapes of panRAF and MEK inhibitors for NRAS vs BRAF mutant melanomas.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!